Mandatory Folic Acid Food Fortification to Prevent Neural Tube Defects: The Pro or Con Debate
American Journal of Internal Medicine
Volume 6, Issue 4, July 2018, Pages: 66-72
Received: Jun. 15, 2018;
Accepted: Jul. 9, 2018;
Published: Aug. 4, 2018
Views 1317 Downloads 131
Evangelia Chrysanthopoulou, Department of Intensive Care Unit, Attiko University Hospital, Haidari, Greece
Irene Karampela, Department of Intensive Care Unit, Attiko University Hospital, Haidari, Greece
Chrysi Diakaki, Department of Intensive Care Unit, Attiko University Hospital, Haidari, Greece
Maria Theodorakopoulou, Department of Intensive Care Unit, Attiko University Hospital, Haidari, Greece
Apostolos Armaganidis, Department of Intensive Care Unit, Attiko University Hospital, Haidari, Greece
Neural tube defects are the second most common congenital anomaly. Among the known risk factors, low levels of folic acid rank first as responsible for the majority of cases recorded worldwide. In 1986, the mandatory folic acid food fortification in the U.S.A. led to dramatic reduction of disease incidence, while for many people it was considered as one of the most successful interventions in the history of public health promotion. Despite the satisfactory results from all countries that adopted similar policies, a significant number of countries, including the EU, preferred alternative ways to address it, considering the very limited safety data for such an intervention. Today, after 20 years of mandatory fortification from a sufficiently representative sample (1/3 of the planet), the necessity to apply this at global level should probably be reviewed, since until now no correlation with unfavourable impacts has been demonstrated. Objective of the present review was to assess the necessity of mandatory folic acid food fortification in the context of congenital neural tube defects (NTDs) prevention. Material – Method: an extensive search in the electronic database PubMed was performed. Animal or in vivo studies and articles were excluded, due to the inability to draw conclusions that is frequently observed, as well as the strong suspicion of failure to respond to clinical data. Furthermore, part of the studies was derived from searches to the References of the articles of the aforementioned database. Conclusions: the decision of mandatory folic acid food fortification should be determined by specific factors as: disease prevalence, rates of planned pregnancies, efficiency of existing measures to decrease significantly the overall disease’s incidence and the folate level in the general population.
Mandatory Folic Acid Food Fortification to Prevent Neural Tube Defects: The Pro or Con Debate, American Journal of Internal Medicine.
Vol. 6, No. 4,
2018, pp. 66-72.
Stover PJ. Folic Acid. Modern Nutrition in Health and Disease. 11th ed. Ross. AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, editors. Wolters Kluwer, Lippincott Williams and Wilkins. 2014. ch 26; p. 358-366.
Mc Lone DG and Bowman RM. In: Up To Date, Post TW (Ed), UpTo Date, Waltham, MA. Pathophysiology and clinical manifestations of myelomeningocele (spina bifida). Last updated May 24, 2018.
EUROCAT Folic Acid Working Group. Prevention of Neural Tube Defects by Periconceptional Folic Acid Supplementation in Europe. Updated version Dec., 2009.
MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991; 338 (8760):131-7.
Czeizel EA, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992; 327(26):1832-5.
Williams J, Mai CT, Mulinare J, Isenburg J, Flood TJ, Ethen M, Frohnert B, Kirby RS. Updated Estimates of Neural Tube Defects Prevented by Mandatory Folic Acid Fortification — United States, 1995–2011. MMWR. 2015; 64 (01): 1-5.
Crider KS, Bailey LB, Berry RJ. Folic Acid Food Fortification—Its History, Effect, Concerns, and Future Directions. Nutrients. 2011; 3(3): 370–384.
De Wals P, Tairou F, Van Allen MI, Soo-Hong U, Lowry RB, Sibbald B, Evans JA, Van den Hof MC, Zimmer P, Crowley M, et al. Reduction in Neural-Tube Defects after Folic Acid Fortification in Canada. N Engl J Med 2007; 357: 135-142.
Castillo-Lancellotti C, Tur JA, Uauy R. Impact of folic acid fortification of flour on neural tube defects: a systematic review. Public Health Nutrition. 2013; 16 (5): 901-911.
Seidahmed MZ, Abdelbasit OB, Shaheed MM, Alhussein KA, Miqdad AM, Khalil MI, Al-Enazy NF, Salih MA. Epidemiology of neural tube defects. Saudi Med J. 2014; 35 (Suppl 1): S29–S35.
Boulet SL, Yang Q, Mai C, Kirby RS, Collins JS, Robbins JM, Meyer R, Canfield MA, Mulinare J. Trends in the postfortification prevalence of spina bifida and anencephaly in the US. Birth Defects Res A Clin Mol Teratol. 2008; 82 (7):527-532.
Barboza-Argüello MP, Umana-Solis LM, Azofeifa A, Valencia D, Flores AL, Rodríguez-Aguilar S, Thelma Alfaro-Calvo T, Mulinare J. Neural Tube Defects in Costa Rica, 1987–2012:Origins and Development of Birth Defect Surveillance and Folic Acid Fortification. Matern Child Health J. 2015; 19(3): 583-590.
Nazer JH, Cifuentes LO. Effects of wheat flour fortification with folic acid on the prevalence of neural tube defects in Chile. Rev Med Chil. 2013;141(6): 751-7.
Cortés F, Mellado C, Pardo RA, Villarroel LA, Hertrampf E. Wheat flour fortification with folic acid: changes in neural tube defects rates in Chile. Am J Med Genet A. 2012;158A (8):1885-90.
Rosenthal J, Casas J, Taren D, Alverson CJ, Flores A, Frias J. Neural tube defects in Latin America and the impact of fortification: a literature review. Public Health Nutr. 2013; 17 (3):537-50.
Amarin ZO Obeidat AZ. Effect of folic acid fortification on the incidence of neural tube defects. Paediatr Perinat Epidemiol. 2010; 24 (4):349-51.
Safdar OY, Al-Dabbagh AA, AbuElineen WA, Kari JA. Decline in the incidence of neural tube defects after the national fortification of flour (1997-2005). Saudi Med J. 2007; 28 (8):1227-9.
Goetzl LM. In: Up To Date, Post TW (Ed), Up To Date, Waltham, MA. Folic acid supplementation in pregnancy. Last updated June 4, 2018.
Centers for Disease Control. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 1992; 41 (No. RR-14)
Agopian AJ, Tinker SC, Lupo PJ, Canfield MA, Mitchell LE. Proportion of neural tube defects attributable to known risk factors. Birth Defects Res A Clin Mol Teratol. 2013; 97 (1):42-6.
Lawrence, M. Fortification. Folic acid and spina bifida. Is it safe? Is it wise? Is it right? [Commentary]. World Nutrition. 2013; 4(3):95-111.
European Food Safety Authority (EFSA). ESCO Report on Analysis of Risks and Benefits of Fortification of Food with Folic Acid. EFSA Supporting Publication 2009; 6 (8): 115.
EUROCAT Special Report. Primary Prevention of Congenital Anomalies in European Countries. 2013.
Busby A, Abramsky L, Dolk H, Armstrong B, Addor MC, Anneren G, Armstrong N, Baguette A, Barisic I, Berghold A et al. Preventing neural tube defects in Europe: a missed opportunity. Reprod Toxicol. 2005; 20 (3):393-402.
Botto DL, Lisi A, Robert-Gnansia E, Erickson JD, Vollse SE, Mastroiacovo P, Botting B, Cocchi G, de Vigan C, de Walle H et al. International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? BMJ 2005; 330: 571.
McDonnell R, Delany V, O'Mahony MT, Mullaney C, Lee B, Turner MJ. Neural tube defects in the Republic of Ireland in 2009-11. J Public Health (Oxf). 2015; 37 (1):57-63.
Evans SE, Mygind VL, Peddie MC, Miller JC, Houghton LA. Effect of increasing voluntary folic acid food fortification on dietary folate intakes and adequacy of reproductive-age women in New Zealand. Public Health Nutr. 2014; 17 (7): 1447-53.
Porettia A, Anheiera T, Zimmermann R, Boltshausera E and the Swiss Paediatric Surveillance Unit (SPSU). Neural tube defects in Switzerland from 2001 to 2007: are periconceptual folic acid recommendations being followed? Swiss Med Wkly. 2008; 138 (41–42): 608–613.
Knudsen VK, Orozova-Bekkevold I, Rasmussen LB, Mikkelsen TB, Michaelsen KF, Olsen SF. Low compliance with recommendations on folic acid use in relation to pregnancy: is there a need forfortification? Public Health Nutr. 2004;7(7):843-50
Friberg AK, Jorgensen FS. Few Danish pregnant women follow guidelines on periconceptional use of folic acid. Dan Med J. 2015; 62 (3):A5019.
Esteller, M. Epigenetics in Cancer. Ρeview article N Engl J Med. NEJM. 2008; 358: 1148-1159.
Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA Methylation: A Review of Molecular Mechanisms and the Evidence for Folate’s Role. Adv Nutr 2012; 3(1):21-38.
Kim SE, Masih S, Kim YI. Folate, DNA Methylation, and Colorectal Cancer; Nutrition and epigenetics. Ho E, Domann F, editors. 2015, section II, ch. 4, pg 113-161.
Keum N, Giovanucci EL. Folic Acid Fortification and Colorectal Cancer Risk. Am J Prev Med. 2014; 46(3 Suppl 1):S65-72.
De Batlle J, Ferrari P, Chajes V, Park JY, Slimani N, McKenzie F, Overvad K, Roswall N, Tjønneland A, Boutron-Ruault MCet al. Dietary Folate Intake and Breast Cancer Risk: European Prospective Investigation Into Cancer and Nutrition. J Natl Cancer Inst. 2014;107(1):367.
Ulrich CM, Potter JD. Folate and Cancer—Timing Is Everything. JAMA. 2007;6;297(21):2408-9.
Jaszewski R, Misra S, Tobi M, Ullah N, Naumoff JO, Kucuk O, Levi E, Axelrod BN, Patel BB, Majumdar A. Folic acid supplementation inhibits recurrence of colorectal adenomas: A randomized chemoprevention trial. World J Gastroenterol. 2008;14(28):4492–4498.
Kim, Young-In. Will mandatory folic acid fortification prevent or promote cancer?. Commentary. Am J Clin Nutr. 2004;80(5):1123-1128.
Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Carol A. Burke CA et al.Folic Acid for the Prevention of Colorectal Adenomas. A Randomized Clinical Trial. JAMA. 2007;297(21):2351-2359.
Qin X, Cui Y, Shen L, Sun N, Zhang Y, Li J, Xu X, Wang B, Xu X, Huo Y et al. Folic acid supplementation and cancer risk: A meta-analysis of randomized controlled trials. Int. J. Cancer. 2013;133:1033–1042.
Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, Armitage J, Manson JE, Hankey GJ, Spence JD et al. Effects of folic acid supplementation on overall and site-specifi c cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals. Lancet. 2013;381:1029–36.
Wang R, Zheng Y, Huang JY, Zhang AO, Zhou YH, Wang JN. Folate intake, serum folate levels, and prostate cancer risk: a meta-analysis of prospective studies. BMC Public Health. 2014;14:1326.
Johnston, RB. Will Increasing Folic Acid in Fortified Grain Products Further Reduce Neural Tube Defects without Causing Harm?:Consideration of the Evidence. Review article. Pediatric Research Vol. 63, No. 1, 2008. Pediatric Research. 2008;63(1):2-8.
Mills JL, Von Kohorn I, Conley MR, Zeller JA, Cox C, Williamson RE, Dufour DR. Low vitamin B-12 concentrations in patients without anemia: the effect of folic acid fortification of grain. Am J Clin Nutr. 2003;77(6):1474-7.
Quinlivan EP, Gregory JF. Effect of food fortification on folic acid intake in the US. Am J Clin Nutr. 2003; 77(1):221-5.
Smith AD, Kim YI, Refsum H. Is folic acid good for everyone? Commentary. Am J Clin Nutr. 2008; 87(3):517-33.
Ziaei S, Norrozi M, Faghihzadeh S, Jafarbegloo E. A randomised placebo-controlled trial to determine the effect of iron supplementation on pregnancy outcome in pregnant women with haemoglobin ≥ 13.2 g/dl. BJOG. 2007;114(6):684-8.
Bo S, Menato G, Villois P, Gambino R, Cassader M, Cotrino I, Cavallo-Perin P. Iron supplementation and gestational diabetes in midpregnancy. Am J Obstet Gynecol. 2009; 201(2):158.
Rioux FM, LeBlancb CP. Iron supplementation during pregnancy: what are the risks and benefits of current practices? Applied Physiology, Nutrition, and Metabolism. 2007;32(2):282-88.